{'fraction_non_alphanumeric': 0.026637069922308545, 'fraction_numerical': 0.00776914539400666, 'mean_word_length': 5.681481481481481, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Effect of co-dergocrine mesylate on catecholamines and prolactin in elderly hypertensive patients].

The antihypertensive efficacy of co-dergocrine mesylate (a mixture of dihydroergocornine mesylate, dihydroergocristine mesylate, and alpha- and beta-dihydroergocryptine mesylates; Hydergin) and its effects on heart rate, plasma catecholamines, catecholamine excretion and plasma prolactin was tested in 12 elderly hypertensive patients. Co-dergocrine mesylate (6 mg or 12 mg, 1 or 2 tablets once a day) caused a significant reduction of the blood pressure during rest and under physical stress without a reactive increase of the heart rate. Plasma norepinephrine and prolactin as well as urinary excretion of norepinephrine and epinephrine were not affected by co-dergocrine mesylate. The therapeutic advantage of co-dergocrine mesylate for the treatment of hypertension in the elderly is discussed.